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Abstract
Background: Chitosan is a dietary fibre which acts by reducing fat absorption and thus used as a means for controlling
weight. Weight loss clinical trial outcomes, however, have contradictory results regarding its efficacy. The primary
objective of the present study was to evaluate the efficacy and safety of a chitosan from fungal origin in treatment of
excess weight in the absence of dietary restrictions.
Methods: A phase IV, randomised, multicentre, single-blind, placebo-controlled, clinical study was conducted by
administering chitosan capsules (500 mg, five/day) and indistinguishable placebo capsules as daily supplements
to 96 overweight and obese subjects for 90 days. The study participants were divided in 2:1 ratio to receive either
chitosan (n = 64) or placebo (n = 32). Efficacy was assessed by measuring body weight, body composition parameters,
anthropometric measurements, HbA1C level and lipid profile at day 45 and day 90. Also, short form-36 quality of life
(QoL) questionnaire was assessed to evaluate improvement in life-style and dietary habits were recorded for calorie
intake. Safety was assessed by evaluating safety parameters and monitoring adverse events.
Results: The mean changes in body weight were -1.78 ± 1.37 kg and -3.10 ± 1.95 kg at day 45 and day 90 respectively in
chitosan group which were significantly different (p < 0.0001) as compared to placebo. BMI was decreased by10.91 fold
compared to placebo after 90 day administration. In concert with this, there was also reduction in body composition
and anthropometric parameters together with improvement in QoL score. Chitosan was also able to reduce HbA1C
levels (below 6 %) in subjects who had initial higher values. The mean caloric intake shows that there was no change
in dietary habits of subjects in both groups. Lipid levels were unaffected and all adverse events were mild in nature
and unrelated to study treatment.
Conclusion: Chitosan from fungal origin was able to reduce the mean body weight up to 3 kg during the 90 day study
period. Together with this, there was also improvement in body composition, anthropometric parameters and HbA1C,
reflecting overall benefits for the overweight individuals. Additionally, there was also improvement in QoL score. It was
safe and well tolerated by all subjects.
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Background
Obesity is a prevalent health hazard in developed and
developing countries and is closely associated with vari-
ous pathological disorders, including diabetes, hyperten-
sion, and cardiovascular diseases [1]. In simple terms, it
may be defined as a state of imbalance between calories
ingested versus calories expended which would lead to
excessive or abnormal fat accumulation [2]. Newer clas-
sifications of obesity are based on simple measures such
as waist hip ratio, total adiposity and intra-abdominal
fatness. Anthropometric indexes such as the body mass
index (BMI) and waist-to-hip ratio (WHR) remain the
most commonly used tools for assessing body compos-
ition because of their simplicity and low cost [3].
International Association for the Study of Obesity
(IASO), and the International Obesity Task Force
(IOTF) estimated, in a study jointly conducted in 2010,
that approximately 1.5 billion adults were overweight
with around 475 million obese adults. Globally, IASO/
IOTF also estimated that up to 10 % (~200 million)
school aged children were either overweight or obese,
20 % of which are in European Union [4].
Treatment of obesity includes lifestyle-based interven-
tion (diet, exercise, and behaviour therapy) and medical
or surgical intervention (pharmacotherapy or bariatric
surgery). There are several approaches through which
pharmacotherapies are directed to treat obesity. These
include, limiting the absorption of food, suppressing ap-
petite and reducing food intake, and altering metabolism
or increasing energy expenditure [5]. However, their use
is controversial as these pharmacotherapies are known
to have significant adverse effects [6, 7] and a consensus
on the optimal clinical use of these pharmacological
agents is not fully established yet, and additional large
clinical studies are needed [8]. One of the most efficient
and safe method would be a reduction in fat intake, as
obesity is directly associated with total fat consumption
[9]. One such substance which acts by reducing the diet-
ary absorption of fat is chitosan.
Chitosan is a popular dietary fibre often used to pre-
vent dietary fat absorption as a means for controlling
weight. It is a cationic polysaccharide produced by dea-
cetylation (hydrolysis of the N-acetyl-D-glucosamine
units) of the biopolymer chitin, which is derived from
the cuticles of crustaceans such as shrimp, crab, and lob-
ster [10], or from the cell wall of mushroom [11]. The
properties of chitosan are similar to cellulose [12]. The
cationicity of chitosan is due to the non-acetylated
amines of the polyglucosamine residues that make up
the polymer chains [13]. Due to its cationic nature, chi-
tosan binds to negatively charged lipids, hence reducing
their gastrointestinal uptake and also potentially lower-
ing serum cholesterol [14]. There are number of reports
which demonstrate that chitosan binds dietary lipids and
bile acids in in-vitro, pre-clinical and human studies
[15–19]. The effects of chitosan as a treatment for over-
weight and obesity has been evaluated in many clinical
trials of great variability in terms of study design and qual-
ity resulting to somewhere inconsistent results [20–25].
However, most of the randomised double-blind placebo-
controlled trials have reported that it may decrease body
weight and serum lipids [10, 20–23, 25, 26] while a few
studies have found no effect of chitosan on clinical out-
comes [12, 24]. Among the reasons for these variable out-
comes are inadequate dosage of chitosan and/or variation
of caloric intake throughout the study (changes in food
habits/inconsistent diet). In order to investigate the effect
of chitosan at a daily dose of 2.5 g, we conducted a rando-
mised, placebo-controlled clinical trial to evaluate the
safety and efficacy of KiOnutrime-CsG® capsules
(Chitosan, 500 mg) in treatment of excess weight in the
absence of dietary modifications. KiOnutrime-CsG®
(KitoZyme, Belgium) is a non-animal chitosan obtained
from the cell walls of the non-genetically modified Asper-
gillus niger mycelium, a by-product of citric acid
production. KiOnutrime-CsG® is an alternative to
crustacean-derived chitosan.
Methods
This was a 90 days, phase IV, randomised, multicentre,
single-blind, placebo-controlled, clinical study conducted
at four hospital sites in cities of Ahmedabad and Bangalore
in India. The study protocol and protocol-related docu-
ments were approved by the institutional ethics committee
of each site before initiating any trial related activity.
Study participants
For preliminary phase screening, a total of 177 study
participants either included in hospital’s databases or
under doctor’s referral were initially contacted. Out of
this, 102 subjects were selected for screening and 75
subjects were not selected based on the reasons de-
scribed in Fig. 1. Subjects of both genders were screened
based on inclusion criteria and were included in the trial
if they were aged 18 to 65 years, who expressed interest
to participate in the study, had BMI between 26 and 35
(both inclusive), willing to comply with the study sched-
ule and procedure. The exclusion criteria were history of
surgical procedure(s) in the past 6 months, history of
invasive fat reduction procedure (e.g., liposuction,
abdominoplasty, mesotherapy) within the past one year,
history of subcutaneous injections (e.g., heparin, insulin)
within the past one month, subject on stable dose of
metformin, pioglitazone or on glucagon-like peptide
analogues, subjects with history of bleeding disorder,
subjects with history of allergy to chitosan, subjects with
treatment of fat soluble vitamins and minerals or other
dietary aids, subjects with poorly controlled diabetes
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mellitus or hypertension, subjects having inflammatory
diseases of the gastrointestinal tract, female subjects
who are pregnant or willing to get pregnant, not ready
to use contraceptive measures during the trial period, or
is breast feeding or in preparations used in the treatment
of menopause disorders and subjects who are taking or
has taken diet pills or supplements within the past
30 days. All study participants provided voluntary
written informed consent before initiating the screening
procedures. Audio-video recording of the entire
informed consent process was carried out according to
the schedule Y of Indian GCP.Out of the 102 screened
subjects, 96 subjects were enrolled in the study. Each en-
rolled subjects received Subject Information Sheet and
Subject diary containing details of food consumption
and drug compliance. They were instructed not to
change their routine dietary habits.
Randomisation, medication dosing and dispensing
Study subjects were randomized in a 2:1 ratio to receive
chitosan (KiOnutrime-CsG® capsules) or indistinguish-
able placebo capsules. This 2:1 ratio was decided to limit
the exposure of placebo formulation to half of the
subjects only. The study medications were dispensed in
pre-labelled identical bottles to all sites according to
individual site randomisation schedule generated using a
computerised random number generator with mixed
block sizes to prevent the identity of treatment assign-
ment. There was no stratification by sex or other demo-
graphic variables.The randomisation codes were kept in
an individually sealed, opaque envelope and broken only
after the completion of data lock procedures.
The chitosan used in the study was chitosan derived
from Aspergillus niger. Each capsule of KiOnutrime-
CsG® contained 500 mg chitosan with excipients
(magnesium stearate and colloidal silicone dioxide). In
case of placebo, chitosan was replaced with 500 mg
microcrystalline cellulose powder and the excipients
were colloidal silicone dioxide, colour yellow oxide
ofiron and colour natural caramel (in order to match
KiOnutrime-CsG® colour). Each bottle of study medica-
tion contained 75 capsules for total 15 days administra-
tion. Subjects were instructed to take one capsule in the
morning, 2 capsules 15 min before lunch and 2 capsules
15 min before dinner with a glass of water. They were
instructed to fill up the time of drug administration and
the number of capsules taken in the subject diary.
Subjects were also instructed to visit the study centre
every 15 days to receive new medication containers and
to assess medication compliance from the subject diary.
Abbreviations: LTF–Lost to follow-up; WC –Withdrawn consent 
Fig. 1 Disposition of subjects
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Dosage compliance was assessed counting the unused
quantity of medication from returned bottles. Medication
compliance was considered reached when there was 90 %
capsules intake over a period of 90 days capsules adminis-
tration. Subjects were also advised to maintain their nor-
mal routine diet and to record the type and amount of
food consumed (for periods of 5 days between days 1–5,
days 41–45 and days 86–90) in the food diary provided, to
calculate and analyse the daily caloric value.
Study visits and evaluations
Subjects visited the study centre four times for evalu-
ation of study parameters: during screening (Visit 1; Day
-5 to 0), enrolment/randomisation visit (Visit 2; Day 1),
follow-up visit (Visit 3; Day 45 ± 2) and end of study visit
(Visit 4; Day 90 ± 3). At each study visit except random-
isation visit, demographic data, anthropometric determi-
nations (includes upper abdominal circumference, hip
circumference, waist circumference and waist to hip
ratio), body composition (BMI, body fat, visceral fat,
muscle mass), HbA1c, lipid parameters (triglyceride,
HDL, LDL, VLDL), and biochemistry data (urea, serum
creatinine, SGPT, SGOT) were evaluated to determine
safety and efficacy of KiOnutrime-CsG®. Physical exami-
nations and vital signs (radial pulse, blood pressure,
respiratory rate, and body temperature) were carried out
at all visits.
Body weight and body composition parameters were
measured using calibrated Body Fat Monitor (Tanita
Corporation, Japan; Model BC 601), which assesses body
composition indirectly by multifrequency bioelectrical
impedance analysis. Anthropometric determinations
were made using non-stretch measuring tape to the
nearest 0.1 cm. Fasting blood was collected onsite and
then transferred within 30 min to central pathology la-
boratory (Dr Lal Pathlabs at Ahmedabad and Bangalore,
India). Serum samples were separated (4000 rpm,
15 min, 4 °C), immediately frozen and stored at -20 °C
until analysed. This was thawed and allowed to come to
room temperature just before the estimation of HbA1c
by immunoturbidimetry assay (Bio-Rad Laboratories,
India; Model D-10), lipid parameters by direct enzymatic
colorimetric assay and biochemistry determinations
(SGPT and SGOT by IFCC method; urea by urease kin-
etic method; creatinine by buffered Jaffe’s method)
(Roche Diagnostic Limited, Switzerland; Model Cobas
Integra 400 plus). All analyses were completed within
12 h of blood collection and all methods were validated
by three freeze-thaw cycles.
Study participants also completed a SF-36 (Short
Form 36) health-related quality of life (QoL) question-
naire [27, 28] at each visit except the randomisation
visit. As part of the questionnaire, SF-36 assessed sub-
jects’ health-related quality of life. The questionnaire
consisted of eight multi-item dimensions. They were
physical functioning (PF), limitations due to physical
problems (Role-Physical), vitality (VT), bodily pain
(BP), social functioning (SF), limitations due to emo-
tional problems (Role-Emotional), mental health (MH),
and general health (GH). The scores from these dimen-
sions were further grouped into physical and mental
components expressed as Physical Component Sum-
mary (PCS) and Mental Component Summary (MCS)
scores. The PCS score reflected physical morbidity and
adaptation to disease, whereas the MCS score referred
to mental morbidity and adaptation.
Assessment of daily average calorie intake was also
carried out by recording the subjects’ diet from their
food diary to confirm whether there wasany influence of
diet on the observed weight loss. This was assessed by
an independent dietician. The average calorie intake for
the period of day 1–5, day 41–45 and day 86–90 was
calculated for both the groups.
End points and measures of outcomes
The primary efficacy end point was reduction in body
weight in kilograms on day 45 and day 90 compared to
baseline. Secondary outcome measures include mean
changes in body composition data (BMI, body fat, vis-
ceral fat, muscle mass), anthropometric values (change
in upper abdominal circumference, hip circumference,
waist circumference and waist to hip ratio), lipid profile
and HbA1c levels.
Safety was evaluated by clinically and physically ob-
serving and reporting adverse events (AE) and assessing
changes in vital signs, and biochemistry parameters.
Change in SF-36 QoL scale from baseline was also
assessed to evaluate safety and efficacy of KiOnutrime-
CsG® capsules.
Statistical analyses
The sample size of this study was based on the primary
objective of reduction in the body weight after 90 days
treatment with chitosan. Based on a power of 95 % due
to higher variation among Indian subjects and a type I
error rate of 0.05 (2-tailed), a sample size of at least 72
subjects (48 in KiOnutrime-CsG® group and 24 in pla-
cebo group after considering randomization ratio of 2:1)
is required to detect a clinically significant difference of
2 kg reduction in body weight after chitosan treatment
with a standard deviation of 2.69 based on previous
published study [1]. Considering dropout rate of 20 %,
adjusted sample size will be 90 (60 subjects in
KiOnutrime-CsG® group and 30 subjects in placebo
group after considering randomization ratio of 2:1).
All the statistical analyses were carried out using SAS
v9.0 (SAS Institute Inc, Cary, NC, USA). Results were
expressed as mean ± standard deviation (SD). The
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distribution of the variables was investigated using the
Kolmogorov-Smirnov test. To evaluate the effect of
chitosan capsules on the investigated variables, P value
for between groups comparison was calculated using
unpaired t- test or Mann Whitney test based on the dis-
tribution of data. In case of within group comparison,
data were analysed using paired t-test or Wilcoxon test
depending upon the distribution of data. P values of less
than 0.05 were considered as statistically significant
difference between and within treatment groups.
Results
Disposition of subjects
Of the 102 subjects screened, a total of 96 subjects were
enrolled in the study. Of these, 64 subjects were ran-
domly assigned to the chitosan group and 32 to the pla-
cebo group. Five subjects from chitosan group and one
from placebo group were lost to follow-up; while three
subjects from chitosan group and one from placebo
group withdrew their consent during the course of the
study. A total of 86 subjects completed the study.
Figure 1 describes the disposition of the study subjects.
Demography& subject characteristics
Baseline demographic characteristics (mean ± SD) for
subjects in the chitosan group were, age 35.53 (± 11.23)
years; weight and height 80.13 (± 11.47) kg and 1.61
(± 0.10) m, respectively and for the placebo group
were, age 36.28 (± 10.49) years; weight and height
80.54 (± 12.68) kg and 1.61 (± 0.09) m,respectively.
There was no significant difference between the baseline
demographics of study participants in each treatment
group (Table 1). A total of 15 subjects in chitosan group
and 6 subjects in placebo group had hypertension,
diabetes mellitus, dyslipidemia or their combination.
Efficacy analyses
Reduction in the mean body weight over a period of 45
and 90 days intervention for chitosan and placebo group
was assessed. In chitosan group, body weight was re-
duced from 80.13 ± 11.47 kg at baseline to 77.75 ± 11.56
at day 45 and 76.89 ± 11.88 kg at the end of 90 days,
which was statistically significant (p < 0.0001) when
compared with baseline measurements. While in placebo
group the body weight was 80.54 ± 12.68 kg at baseline,
which minimally changed to 80.89 ± 12.15 kg at 45 days
and 80.76 ± 12.31 kg at the end of 90 days of treatment,
which was statistically non-significant. It is noteworthy
that in chitosan group, the percentage of subjects who
reduced body weight in the range of up to 2 kg, 2–4 kg
and >4 kg was 54.2 % (n = 32), 28.8 % (n = 17) and
10.2 % (n = 6) at the end of day 45 and 10.7 % (n = 6),
48.2 % (n = 27) and 33.9 % (n = 19) at the end of day 90,
respectively. While in the placebo group, the percentage
of subjects who reduced body weight in the same range
was 41.9 % (n = 13), 12.9 % (n = 4) and 0 % (n = 0) at day
45 and 40.0 % (n = 12), 10.0 % (n = 3) and 3.3 % (n = 1)
at the end of day 90, respectively. Only about 6.8 %
(n = 4) subjects at day 45 and 7.1 % (n = 4) subjects at
day 90 were non-responders in chitosan group, while
in placebo group, the percentage of non-responders
were 45.2 % (n = 14) and 46.7 % (n = 14) subjects at
day 45 and day 90, respectively.
In chitosan group, the mean change in body weight
was -1.78 ± 1.37 kg (range: -5.30 to 0.80 kg) and -3.10 ±
1.95 kg (range: -9.00 to 1.90 kg) at day 45 and day 90,
respectively. These results were significantly different
(p < 0.0001) as compared to placebo where mean
change in body weight was -0.31 ± 1.30 kg (range:
-3.00 to 2.50 kg) and -0.33 ± 1.51 kg (range: -4.60 to
2.80 kg), respectively (Fig. 2).Table 2 shows the
comparison between body weights in both the groups.
Other study parameters
Table 3 describes the absolute values of each study pa-
rameters at baseline, at day 45 and day 90 and Table 4
describes the change in each parameter at day 45 and
day 90 from baseline.
Mean BMI decreased significantly (p < 0.0001) over
the period of 90 days in chitosan group (30.93 ± 2.69 at
baseline to 30.20 ± 2.90 at day 45 and 29.71 ± 3.07 at day
90), while in placebo group it was decreased minimally
but was not significant (p = 0.3846) as compared to base-
line values (30.91 ± 2.72 at baseline to 30.95 ± 2.62 at day
45 and 30.83 ± 2.64 at day 90) (Table 3). Mean change in
the reduction of BMI from baseline was significantly
higher in chitosan group on day 45 and day 90 as com-
pared to subjects receiving placebo (Table 4).In chitosan
group the mean changes in BMI at day 45 were found to
be in the range of -2.15 to +0.32 (mean -0.69), while the
Table 1 Demographics of study participants
Subject characteristic Chitosan (N = 64) Placebo (N = 32)
Age (years) [range] 35.53 ± 11.23 [19–63] 36.28 ± 10.49 [18–56]
Gender (male /female) M = 25; F = 39 M = 11; F = 21
Weight (Kg) [range] 80.13 ± 11.47 [54.0–106.5] 80.54 ± 12.68 [59.8–116.0]
Height (M) [range] 1.61 ± 0.10 [1.38–1.82] 1.61 ± 0.09 [1.47–1.83]
Values are expressed as Mean ± Standard deviation (SD). Gender expressed as absolute number. N = number of patients. Data are presented as descriptive statistics
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same for placebo was in a range of -1.19 to +1.01
(mean -0.11). After 90 days of administration, there
was a further reduction in BMI in chitosan group which
was in the range of -3.65 to +0.73 (mean -1.20) as com-
pared to -1.81 to +1.14 (mean -0.11) in placebo group.
Similarly, body fat was significantly reduced (p < 0.0001)
in subjects administered with chitosan at the end of
90 days (37.88 ± 6.86, 37.36 ± 7.03 and 36.65 ± 7.25 at
baseline, day 45 and day 90 respectively) (Table 3), while it
was increased slightly in placebo group (p = 0.5684).
However, there was no statistical difference between both
treatments at any time points. Mean changes in body fat
reduction from baseline in chitosan group as compared to
placebo group at day 45 (-0.38 ± 1.17 % vs-0.11 ± 1.12 %)
and day 90 (-0.98 ± 1.27 % vs-0.05 ± 0.98 %) were signifi-
cantly different (Table 4). This mean change in body fat
reduction was in the range of -6.60 to +2.80 % and -6.80
to +2.60 % in chitosan group, while in placebo group it
was -3.70 to +2.80 % and -2.70 to +2.30 % at day 45 and
day 90, respectively.
Visceral fat significantly decreased (p < 0.0001) in sub-
jects administered with chitosan at day 45 (10.47 ± 3.38 %)
from baseline (10.80 ± 3.52). This further decreased to
9.71 ± 3.33 % at the end of 90 days administration
(Table 3). In placebo group, however, visceral fat remained
unchanged at day 45 (10.55 ± 2.75 %) and at the end of
90 days (10.43 ± 2.87 %). Again, when compared between
treatments, the values were statistically non-significant.
But when mean changes in reduction of visceral fat from
baseline was compared (Table 4), it was observed that
chitosan showed significantly higher (p < 0.001) reduction
in visceral fat as compared to placebo on day 90 (1.28 ±
1.12 % vs 0.43 ± 0.85).
We found that muscle mass decreased in chitosan
group (47.52 ± 9.62, 46.74 ± 9.50 and 46.84 ± 9.57 at
baseline, day 45 and day 90 respectively) and increased
in placebo group over a 90-days administration (46.95 ±
10.79, 47.04 ± 11.17 and 47.50 ± 11.01 at baseline, day 45
and day 90 respectively) (Table 3). However, there was
no significant difference between treatments (p = 0.581,
0.798, 0.969 at day 0, 45 and 90 respectively). But when
mean changes in muscle mass from baseline was com-
pared, it was found that at day 90 there was significant
difference (p = 0.0008) between the groups (-0.74 ± 1.57
vs. -0.08 ± 1.16). This can also be observed by reduction
of muscle mass in the range of -11.50 to +1.20 in
chitosan group as compared to -3.20 to +3.10 in placebo
group at day 90 (Table 4).
Fig. 2 Mean body weight changes from baseline
Table 2 Effect of treatments on body weight at day 45 and day 90 (in Kg)
Visit Chitosan (N = 64) Placebo (N = 32) P value between group
Day 0 (n = 64, 32) 80.13 ± 11.47 80.54 ± 12.68 0.87
Day 45 (n = 59, 31) 77.75 ± 11.56* 80.89 ± 12.15 0.43
Day 90 (n = 56, 30) 76.89 ± 11.88* 80.76 ± 12.31 0.35
Change from baseline
Day 45 (n = 59,31) −1.78 ± 1.37@ −0.31 ± 1.30 < 0.0001
Day 90 (n = 56, 30) −3.10 ± 1.95@ −0.33 ± 1.51 < 0.0001
Values are expressed as Mean ± Standard deviation (SD); *p < 0.0001 as compared to baseline (Within group comparison); @ - statistically significant as compared
to placebo at day 45 and day 90; N = Number of subjects in each treatment group. n = number of subjects with non-missing values at respective visit
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The reduction in body weight caused a comparable
decrease in anthropometric measurement as well. There
was significant mean reduction in upper abdominal
circumference, hip circumference and waist circumfer-
ence at day 45 (p < 0.0001) and day 90 (p < 0.0001) from
baseline in subjects treated with chitosan capsules
(Table 3). On the contrary, there was no statistical sig-
nificant reduction in upper abdominal circumference,
hip circumference and waist circumference in patients
treated with placebo on day 45 and day 90. Mean change
in reduction from baseline in upper abdominal circum-
ference (-0.92 ± 1.25 and -2.17 ± 1.98 vs. -0.35 ± 0.95 and
-0.50 ± 1.10), hip circumference (-1.05 ± 1.05 and -2.07 ±
1.51 vs. -0.41 ± 1.14 and -0.66 ± 1.24) and waist circum-
ference (-0.91 ± 1.68 and -1.97 ± 2.20 vs. -0.64 ± 1.22 and
-0.90 ± 1.47) was significantly (p < 0.0001) greater in
subjects treated with chitosan than with placebo at day
45 and day 90, respectively (Table 4). There was no
Table 3 Study parameters values at baseline, day 45 and day 90 in treatment groups
Study parameters Chitosan (mean ± SD) [range] Placebo (mean ± SD) [range]
Day 0 (N = 64) Day 45 (N = 59) Day 90 (N = 56) Day 0 (N = 32) Day 45 (N = 31) Day 90 (N = 30)


































































































Values are expressed as Mean ± Standard deviation (SD). *p< 0.0001 as compared to baseline (Within group comparison). N =Number of patient in each treatment group
Table 4 Mean change from baseline in study parameters
Visit Chitosan (mean ± SD) [range] Placebo (mean ± SD) [range] P value between groups
Body mass index(Kg/m2) Day 45 (n = 59, 31) -0.69 ± 0.53@ [-2.15 – 0.32] -0.11 ± 0.50 [-1.19 – 1.01] < 0.0001
Day 90 (n = 56, 30) -1.20 ± 0.76@ [-3.65 – 0.73] -0.11 ± 0.59 [-1.81 – 1.14] < 0.0001
Body fat (%) Day 45 (n = 59, 31) -0.38 ± 1.17@ [-6.60 – 2.80] -0.11 ± 1.12 [-3.70 – 2.80] 0.034
Day 90 (n = 56, 30) -0.98 ± 1.27@ [-6.80 – 2.60] -0.05 ± 0.98 [-2.70 – 2.30] < 0.0001
Visceral fat (%) Day 45 (n = 59, 31) -0.38 ± 0.71 [-3.0 – 1.0] -0.19 ± 0.54 [-2.0 – 1.0] 0.127
Day 90 (n = 56, 30) -1.28 ± 1.12@ [-4.0 – 1.0] -0.43 ± 0.85 [-2.0 – 2.0] 0.001
Muscle mass (Kg) Day 45 (n = 59, 31) -0.48 ± 1.51 [-11.10 – 1.20] -0.20 ± 0.89 [-2.50 – 2.70] 0.253
Day 90 (n = 56, 30) −0.74 ± 1.57@ [−11.50 – 1.20] -0.08 ± 1.16 [-3.20 – 3.10] 0.0008
Upper abdominal circumference (cm) Day 45 (n = 59, 31) -0.92 ± 1.25@ [-6.0 – 2.0] -0.35 ± 0.95 [-3.0 – 1.0] 0.020
Day 90 (n = 56, 30) -2.17 ± 1.98@ [-8.0 – 2.0] -0.50 ± 1.10 [-3.0 – 1.0] < 0.0001
Hip circumference (cm) Day 45 (n = 59, 31) -1.05 ± 1.05@ [-4.0 – 0.0] -0.41 ± 1.14 [-4.0 – 2.0] 0.0024
Day 90 (n = 57, 30) -2.07 ± 1.51@ [-6.0 – 2.0] -0.66 ± 1.24 [-3.0 – 2.0] < 0.0001
Waist circumference (cm) Day 45 (n = 59, 31) -0.91 ± 1.68@ [-8.00 – 6.00] -0.64 ± 1.22 [-1.00 – 6.00] 0.027
Day 90 (n = 57, 30) -1.97 ± 2.20@ [-8.00 – 7.00] -0.90 ± 1.47 [-1.00 – 7.00] < 0.0001
Waist to hip ratio Day 45 (n = 59, 31) -0.0027 ± 0.02 [-0.13 – 0.04] -0.0035 ± 0.01 [-0.03 – 0.03] 0.091
Day 90 (n = 57, 30) -0.0010 ± 0.02 [-0.13 – 0.07] -0.0033 ± 0.01 [-0.02 – 0.04] 0.768
Values are expressed as Mean ± Standard deviation (SD); N = Number of subjects in each treatment group; @ - statistically significant when compared to placebo;
n = number of patients with non-missing values at respective visit
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significant change in waist to hip ratio in both treatment
groups at day 45 and day 90 (-0.0027 ± 0.02 and -0.0010
± 0.02 vs. -0.0035 ± 0.01 vs.-0.0033 ± 0.01 at p = 0.091
and 0.768).
HbA1c level at baseline was compared with post-
administration measurements at day 45 and day 90 to as-
sess the efficacy of chitosancapsules. In this study, HbA1c
level was significantly decreased at day 45 (5.72 ± 0.78 %)
and day 90 (5.74 ± 0.83 %) in chitosan group as compared
to its baseline value (5.89 ± 0.83), which was statistically
significant (p = 0.0327). However, within placebo group
there was statistically significant reduction (p = 0.0334)
observed at day 45 only as compared to its baseline values,
while at day 90 it again increased and was statistically
non-significant (p = 0.8269) as compared to its baseline
values (Table 5). Further analysis revealed that, there were
17 subjects whose HbA1c levels were above 6 % (mean:
6.55 %; range: 6 to 8.2 %) while the remaining subjects
had HbA1c levels below 6 % (mean: 5.47 %; range: 4.3 to
5.9 %) at baseline. After 90 day treatment with chitosan,
HbA1c level significantly decreased in those17 subjects
(mean: 6.04 %; range: 5.1 to 6.8 %) while in the remaining
subjects, it was unchanged throughout the study period
(mean: 5.48 %; range: 4.7 to 5.9 %). This shows that chito-
san was effective in reducing HbA1c levels in subjects
who were having higher glycaemic value initially, while
subjects with normal glycaemic levels were unaffected.
Analysis of daily food intake for the period of 15 days
(day 1–5, day 41–45 and day 86–90) for calorie intake
showed there was no significant change, in either group,
during this study. The mean caloric intake in chitosan
group for day 1–5 was 1784 kcal, for day 41–45 was
1797 kcal and for day 86–90 was 1750 kcal. While the
same for placebo group was 1761 kcal, 1701 kcal and
1677 kcal, respectively.
Safety analyses
Lipid levels in both treatment groups are described in
Table 5. Although LDL levels increased in chitosan group
at day 45 and in placebo group at day 90, in general the
results were clinically non-significant as this increase in
LDL can be attributed to only two of the subjects; one in
chitosan group and one in placebo group who showed
transient increase in their LDL levels.
The SF-36 analysis shows that the mean PCS score
and mean MCS score obtained in chitosan group at day
0 were 40.99 ± 6.51 and 48.34 ± 6.77, respectively and at
day 90 were 51.32 ± 7.23 and 49.10 ± 7.08, respectively.
The mean PCS score and mean MCS score obtained in
placebo group at day 0 were 41.26 ± 5.78 and 46.16 ±
7.77, respectively and at day 90 were 43.19 ± 7.50 and
47.45 ± 6.60, respectively.Assessment of Quality of Life
(QoL) using SF-36 questionnaire showed statistical sig-
nificant (p < 0.0001) increase in QoL score in subjects
Table 5 Comparison in lipid profile (TG, HDL, LDL and VLDL) and HbA1C levels
Visit Chitosan (N = 56) Placebo (N = 30) P value between groups
TG (mg/dl)
Day 0 145.2 ± 64.35 153.1 ± 76.44 0.753
Day 45 143.7 ± 76.33 160.5 ± 92.92 0.494
Day 90 138.8 ± 63.81 170.3 ± 102.8 0.203
HDL(mg/dl)
Day 0 41.47 ± 7.50 42.87 ± 10.28 0.448
Day 45 44.38 ± 12.01 41.14 ± 9.55 0.285
Day 90 43.17 ± 11.65 42.08 ± 10.74 0.944
LDL (mg/dl)
Day 0 106.9 ± 27.80 107.2 ± 30.39 0.959
Day 45 114.9 ± 42.44* (p = 0.0213) 113.7 ± 38.66 0.746
Day 90 109.9 ± 31.64 115.6 ± 31.93* (p = 0.0266) 0.428
VLDL (mg/dl)
Day 0 29.04 ± 12.87 30.62 ± 15.29 0.746
Day 45 28.74 ± 15.27 32.10 ± 18.59 0.494
Day 90 27.76 ± 12.76 34.07 ± 20.55 0.203
HbA1C (%)
Day 0 5.89 ± 0.83 5.89 ± 0.75 0.912
Day 45 5.72 ± 0.78* (p = 0.0225) 5.80 ± 0.68* (p = 0.0419) 0.661
Day 90 5.74 ± 0.83* (p = 0.0343) 5.88 ± 0.57 0.138
Values are expressed as Mean ± Standard deviation (SD). * = as compared to baseline (Within group comparison). N = Number of patient in each treatment group
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from chitosan group as compared to the placebo group
from baseline to day 90, which depicts improvement in
the QoL (Table 6).
There were a total of 10 adverse events (AEs) recorded
during the study period: four in placebo group and six in
chitosan group. In chitosan group reported AEs were
common cold, hypertriglyceridemia, body ache, constipa-
tion (2 subjects) and hypertension, while in placebo group,
the reported AEs were mild headache (2 subjects),
hypertriglyceridemia and fracture. All adverse events were
mild in nature and unrelated to the study treatment.There
was no statistically significant difference in laboratory
parameters (SGOT, SGPT, serum creatinine and urea)
from baseline to day 90 in both chitosan and placebo
groups. No dropout was observed due to AEs, which
states that overall the study treatment was safe and well
tolerated by all study subjects.
Discussion
This study demonstrates that administration of chitosan
(KiOnutrime-CsG® capsules, 500 mg, 5 capsules/day in
three divided doses) results in a significant mean weight
loss of about 3 kg without diet restriction over a period
of 90 days. The observed weight loss in chitosan group
is in contrast to only 0.3 kg weight loss in placebo group.
Also significant was the percentage of subjects who lost
between 5 and 10 % of body weight after 90 days com-
pared to placebo group (32.4 and 3.3 %, respectively).
Although some studies demonstrated that reduction in
body weight by administration of chitosan can be
achieved in individuals given a hypocaloric or standard-
ized diet [14, 29], other studies show efficacy of chitosan
for persons without diet restrictions [10, 23, 30, 31]. The
results of our study confirm that indeed significant
weight loss can be achieved in subjects adhering to a
non-restrictive diet [10, 23, 30, 31]. Reasons for the dif-
ference in results in our study with other reported
studies could be difference in diets, dosage and timing of
chitosan administration or protocol variability such as
life style recommendations.
One factor which is important to consider is the timing
of chitosan ingestion before meals. It is typically recom-
mended that chitosan supplements be ingested approxi-
mately 15 min to 1 h prior to a meal in order to allow
sufficient time for chitosan to dissolve in the stomach
acid[18]. In our study, the dosage was one capsule 15 min
before breakfast and two capsules each 15 min before
lunch and dinner. This allowed sufficient time for it to
dissolve properly and efficiently bind the fats present in
the meal, which resulted in observed weight loss.
Body weight gain and increase in BMI are the key clin-
ical features of obesity. BMI correlates fairly well with
total body fat on a population basis [32]. The overweight
(BMI 25.0 to 29.9 kg/m2) and obese (BMI ≥30 kg/m2)
individuals have higher body fat together with increased
risk of cardiovascular and other metabolic disorders. In
this study we found that after 90 day administration with
chitosan, there was 10.91 fold reduction in BMI com-
pared to placebo group. The implications of this result
are that the subjects, who were initially classified as
obese, can now be defined as overweight as their mean
BMI fell below 30 kg/m2.
It is well known that weight reduction in subjects with
obesity has a marked effect on the regulation of lipolysis
[33] and weight loss shows good correlations with sev-
eral of the circumferences [34] that were measured in
present study. Also, in one of the gastric bypass study
conducted by Sjostrom and colleagues [35], it was found
that the profound weight loss experienced by the sub-
jects resulted from a global decrease in body fat rather
than localised loss. Also, hypocholesterolemic properties
of chitosan decrease the risk of atherosclerosis and other
cardiovascular dysfunctions [36]. Chitosan, by the virtue
of its property to bind fat and triglycerides, may also
Table 6 Effect of treatment groups on quality of life score
Visit Chitosan (mean ± SD) [range] Placebo (mean ± SD) [range] P value
PCS Score
Day 0 (n = 58, 31) 40.99 ± 6.51 [22.80 − 56.90] 41.26 ± 5.78 [33.10 − 57.70] 0.869
Day 90 (n = 59, 31) 51.32 ± 7.23*@ [32.10 − 61.80] 43.19 ± 7.50[31.20 − 56.40] < 0.0001
Change from baseline (PCS Score)
Day 90 (n = 59, 31) 10.58 ± 8.07@ [-27.70 – 8.50] 1.93 ± 5.69 [−17.60 – 6.30] < 0.0001
MCS score
Day 0 (n = 58, 31) 48.34 ± 6.77 [27.20 − 60.50] 46.16 ± 7.77 [17.70 − 61.90] 0.173
Day 90 (n = 59, 31) 49.10 ± 7.08 [33.20 − 61.60] 47.45 ± 6.60 [27.90 − 62.40] 0.283
Change from baseline (MCS Score)
Day 90 (n = 59, 31) 0.98 ± 6.73 [-20.80 − 16.70] 1.28 ± 8.81 [-34.30 − 10.60] 0.4755
Values are expressed as Mean ± Standard deviation (SD). * = statistically significant as compared to baseline. @ - statistically significant as compared to placebo at day 90.
N=Number of subjects in each treatment group
Trivedi et al. Nutrition Journal  (2016) 15:3 Page 9 of 12
have caused the disturbances in regulation of lipolysis
resulting in lowering of body fat and visceral fat
observed in our study.
Reduction of muscle mass by chitosan was observed in
this study which is reduced in an average of 0.74 kg over
a period of 90 days. Although there is a statistically sig-
nificant reduction, this has not produced any clinically
relevant adverse effects over a period of 90 days.
It is already reported that chitosan can regulate lipids
with benefit on anthropometric parameters [37]. Also, in
one of the study conducted over a period of five years, it
was confirmed that weight gain and weight loss are asso-
ciated with changes in the anthropometric measure-
ments and waist to hip ratio (WHR) in both genders
[38]. The reduction in body composition and anthropo-
metric parameters observed in our study can be attrib-
uted to general reduction in body weightpossibly due to
reduction in fat absorption [39] by chitosan.
Practically no significant change was observed in
serum triglyceride, LDL and VLDL throughout the test
period while HDL was slightly increased in chitosan
group (non-significant). It is well known that Low-
density lipoproteins (LDL) are considered as important
risk factors for cardiovascular diseases (CVD), while
highdensity lipoproteins (HDL) are well recognized for
their putative role in reverse cholesterol transport [40].
Since HDL-cholesterol is more metabolisable into bile
acid than LDL-cholesterol [41], it is presumed that a
deficiency of bile acid in the body due to binding with
chitosan would accelerate the conversion of cholesterol
to bile acid, which may result in an increase of HDL-
cholesterol. In a similar previous study where effects of
chitosan was studied on lipids and lipoproteins, it was
found that chitosan increased HDL level up to 14 % dur-
ing the 4-month study period [42].
Obesity is a multi-factorial disorder, which is often
associated with many other significant diseases such as
diabetes, inflammation, hypertension and other cardiovas-
cular diseases; there is a consistent graded relationship be-
tween increased BMI and prevalence of non-insulin
dependent diabetes mellitus (NIDDM) and insulin resist-
ance [43]. It is established that inflammation, diabetes and
obesity are interrelated and a person with diabetes are pre-
disposed to obesity and metabolic syndrome. HbA1C re-
flects the long-term glycaemic level and is a marker for
progression of diabetes. In the present study, we observed
that chitosan was able to lower the HbA1C level to less
than 6 % during the 90-days study period. It has been re-
ported that chitosan significantly reduced postprandial
blood glucose levels in both animal and in vitro models
[44] as well as in humans [45]. This may the reason for
the observed decrease in HbA1c levels in our study. Inter-
estingly, this reduction was mainly observed in subjects
who were initially having high HbA1C levels, while
subjects with normal HbA1C levels at baseline were
unaffected by chitosan. However, more clinical studies are
required to confirm this effect of chitosan in large diabetic
population.
The results of SF-36 QoL score showed that there was
significant improvement in mean PCS score in chitosan
group which reflects improvement in physical morbidity
and adaptation to obesity. However, mean MCS score
failed to improve with the treatment. This may be due
to failure to evaluate the impact that excess weight
would have on obesity-specific aspects of QoL score
during the baseline evaluations [46]. This might explain
why no effect of decrease in BMI was detected on MCS
despite it being recognised that people who are over-
weight or obese are more likely to suffer from discrimin-
ation and depression [47]. Another possible explanation
may be that people who are very overweight and obese
may need to loose in excess of 10 % of their body weight
in order to experience a positive impact on QoL [48].
However, only one of the subjects in our study showed
weight loss of more than 10 %, thus explaining the
differences in PCS and MCS score.
Conclusion
In summary, we conclude that KiOnutrime-CsG® cap-
sule, containing 500 mg of chitosan from fungal origin,
was able to reduce the mean body weight up to 3 kg
during the 90-days study period. Together with this,
there was also improvement in body composition, an-
thropometric parameters and HbA1C, reflecting overall
benefits for the overweight individuals. Additionally,
there was also improvement in QoL score. KiOnutrime-
CsG® capsulewas also found to be safe and well tolerated
by all study participants.
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